Curefoods is looking at going IPO with a ₹800 Cr raise. But why? At what valuation? Does it make sense? Read on.

With the rise of Chinese automotive industry, Europe and Japan are sweating bullets, and soon US will too. What do you think will happen in India? Read on.

Adani Group is in the fray to take over Jaiprakash Associates (JAL). This is perhaps one of the most beautifully tragic and humbling corporate stories to have come out of India. Read on.

Would people prefer someone who'd spend Trillions to kill Millions, only to leave their home in an infinitely worse state, all while gaining absolutely nothing.. because of their "decorum"? Read on.

Pharmeasy had raised a total $1.6 Billion at a peak valuation of $5.6 Billion. And now the company is pretty much done and the founders are out. It's quite an interesting story. Read on.

An analysis on the inherent difficulties of Urban Company's business model, and appreciation of how they've dealt with them.

An analysis of Lenskart's valuation considering its recent IPO development.

A lot of Indian actors are starting to position themselves as "entrepreneurs" lately. Many are even getting involved with startups directly. Do you wonder why? Read on.

Mr. Vijay Mallya's dues have been more than recovered, then why is he still being called a fugitive, a fraud, a chor, a lootera? Read on.

A song about a musician at the verge of giving up on his dream. A part of him wants to finally let it go. But can he?

An analysis on OYO winging it at the IPO table with a ticking time bomb underneath. Read on.

Peer reviewers, who are supposed to be validating the research published by pharma companies, have been taking money from the pharma companies themselves. Read on.

Aamir Khan's latest movie, 'Sitaare Zameen Par', is a frame-by-frame copy of Champions, a Woody Harrelson film, which is itself an english remake of a spanish picture called "Campeones".

How valid is this wisdom in the modern age of warfare between two nuclear powers? Read on.

The so called "authority institutions" of the past have lost all their credibility. But why? Read on.

An analysis of the Indian defense budget, how it's worked so critically, and where it could from here.

BluSmart is a crazy story when it comes to related party transactions and financial gymnastics. But what about Ola? Read on.

Mr. Buffett is finally retiring from Berkshire Hathaway at age 94. What would be his greatest insight? Read on.

OYO's third IPO attempt has failed, too. Does it mean the end of the road for Ritesh Agarwal? Read on.

There's a recent trend of calling traditional herbs, medicines and practices as "scams". This narrative is being peddled by people who've assumed the status of final arbiters and faithful protectors of "science". But what's the bedrock of these people's thesis? And is it really scientific? Read on.